Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 21867

Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"

Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018

Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."

Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018

Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."

Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018

Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."

Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
On Sep 2018

Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."

Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata

Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
On Aug 2018

Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".

Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
On Aug 2018

Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".

Dr. Mamta Gupta
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018

Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.

Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."

Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
On May 11,2011

Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."

Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
On April 2011

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.

Dr. Anuradha
On Jan 2020

Important Notice

Year : 2010 | Month : June | Volume : 4 | Issue : 3 | Page : 2550 - 2559 Full Version

Nitric Oxide And Cancer

Published: June 1, 2010 | DOI:

*(MD), Assistant Professor, Department of Radiotherapy, **(MD), Assistant Professor, ***(MD), Senior Professor & Head Department of Biochemistry, ****Resident, Department of Radiotherapy, *****(MD), (DNB), Senior Professor & Head, Department of Radiotherapy, Pt. B.D.Sharma******, PGIMS, Rohtak, Haryana, (India.)

Correspondence Address :
Dr. Kiran Dahiya, 778/28,Bharat Colony, Rohtak,Haryana, (India). PIN: 124001.Mobile: +919896111985,Email:


Nitric oxide (NO) is a pleiotropic biological mediator which plays a key role in various physiological and pathological processes. It is synthesized with the help of the enzyme nitric oxide synthase (NOS), which has three isoforms. All these isoforms of NOS have been reported to be involved in promoting or inhibiting the aetiology of cancer. High levels of NOS expression in tumour cells may be cytostatic or cytotoxic, while low levels can have the opposite effect and may promote tumour growth. NO also has diverse effects in cancer treatment. It can enhance the cytotoxic efficacy of some chemotherapeutic agents as well as radiation. The modification of NOS activity in tumours can be considered to be a promising mean for selective tumour blood flow modification, thus providing a novel approach for reducing tumour oxygenation which is aimed at enhancing the efficiency of hypoxia- mediated, bioreductively activated modalities for cancer treatment.


Nitric Oxide, Nitric Oxide Synthase, Cancer, Chemotherapy, Radiotherapy

Nitric Oxide
Nitric oxide (NO), which was thought to be just one of the polluting gases produced in car exhausts earlier, has been recognised only recently as a reactive molecule with broad and diverse effects in human biology. NO is a hydrophobic diatomic gas that transmits signals in the organism. Signal transmission by a gas that is produced by one cell, penetrates through membranes and regulates the function of another cell, thus representing an entirely new principle for signalling in biological systems (1). It appeared that there was a chemical similarity between endothelium derived relaxation factor (EDRF) and NO. Besides, both compounds exerted vasodilatation by means of cyclic guanosine monophospahte (cGMP) synthesis. The groups of Furchgott and Ignarro independently proposed in 1986 that EDRF was really NO (2). Soon, the group of Moncada (1987) obtained the first results which supported that proposal. Moreover, they demonstrated that endothelial cells produced NO in sufficient amounts to explain the relaxation observed. So, the previous proposal was confirmed (3).

NO is also known as a free radical as it possesses an unpaired electron. A free radical prefers to steal electrons from the lipid membrane of the cell, thus initiating a free radical attack on the cell, which is known as lipid peroxidation (1).

Synthesis of Nitric Oxide
NO is synthesized during the conversion of arginine to citrulline. Nitric oxide synthase (NOS) catalyses the reaction. Three isoforms of NOS have been identified- endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible (iNOS). All have binding sites for nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) near the carboxy terminus (the reductase domain) and the binding sites for tetrahydrobiopterin (BH4) and heme near the amino terminus (the oxygenase domain). The reductase and oxygenase domains are linked by calmodulin binding sites. This enzyme exists in both a constitutive (calcium–dependent) and inducible (calcium- independent) form in endothelial cells, platelets and placental tissue (4),(5).

The calcium-calmodulin complex, in combination with BH4, binds to nNOS and induces its translocation from the plasma membrane to the cytoplasm, as it is soluble in both aqueous and lipid media and also readily diffuses through the cytoplasm and the plasma membrane. NO activates various cGMP–regulating signalling pathways which in turn, enhance the release of neurotransmitters, thus resulting in smooth muscle relaxation and vasodilation (5).

Two families of NOS with molecular weights ranging from 125 to 160 KDa have been isolated. One family is iNOS and its expression is tightly controlled by several transcription factors, the specific inducers being variable with the cell type. Cytokines such as the tumour necrosis factor, interleukin–1 and gamma-interferon have been shown to promote the synthesis of the enzyme. The iNOS is mainly found in macrophages and is often called as macrophage NOS (mNOS) but monocytes, megakaryocytes, fibroblasts, neutrophils, hepatocytes and smooth muscle cells also possess it. The gene of this inducible enzyme is present on chromosome number 17 (1).

The other family is constitutive NOS (cNOS) which is synthesized at a constant rate, regardless of the physiological demand. The constitutive enzymes are regulated by calcium-calmodulin and phosphorylation. According to the sites of productions, the constitutive family of enzymes may be of two subtypes -(a) eNOS is found in the endothelial cells, platelets, the endocardium and the myocardium. The gene for eNOS is present on chromosome number 7. (b) nNOS is seen in the central and peripheral neurons. This enzyme is also termed as brain NOS (bNOS) as it is chiefly found in different areas of the brain. Its gene is present on chromosome number 12. The nNOS and mNOS are found in the cytosol, but the eNOS is predominantly localised in the plasma membrane (1).

NO is inhibited by asymmetrical dimethylarginine (ADMA). ADMA is metabolised by dimethylaminohydrolase (DDAH) and excreted by the kidneys. In 1992, Vallance et al first described the presence of ADMA as an endogenous inhibitor of eNOS in human plasma and urine. Since then, the role of this molecule in the regulation of eNOS has attracted increasing attention. ADMA inhibits vascular NO production within the concentration range which is found in patients with vascular disease. ADMA also causes local vasoconstriction when it is infused intra-arterially and increases systemic vascular resistance and impairs renal function when it is infused systemically. Thus, elevated ADMA levels may explain the ‘L- arginine paradox’; i.e. the observation that supplementation with exogenous L-arginine improves NO-mediated vascular functions in vivo (7).

Biological Actions of Nitric Oxide
The classical pathway by which NO exerts many of its actions is via the activation of the enzyme soluble guanaylate cyclase (sGC) and the resultant conversion of guanosine 5´–triphosphate (GTP) to the second messenger cGMP. However, recent studies have established that NO can also act via cGMP-independent pathways in various systems, particularly during the inhibition of platelet aggregation and the regulation of inflammatory cell apoptosis. NO may have an additional beneficial effect on blood coagulation by enhancing fibrinolysis via an effect on plasminogen (1),(6).

As NO is a free radical, it is a highly reactive molecule within biological systems, reacting with other free radicals, molecular oxygen and heavy metals. It has been suggested that the biological effects of NO can be mediated by the products of different NO metabolites e.g. nitrite, nitrate, S-nitroso-thiols or peroxynitrite. NO has also been reported to bind rapidly and with high affinity to ferrous iron (Fe2+). NO can bind easily to free iron, iron within iron-sulphur centres, and iron within haemoproteins. NO is unusual because it reacts with both the ferric and ferrous forms of heme iron. The binding of NO to ferrous ions is irreversible and occurs with very high affinity i.e. 10,000 times more than for oxygen.3 NO may also be involved in the regulation of protein activity through S-nitrosylation. In the extracellular milieu, NO reacts with oxygen and water to form nitrates and nitrites. The toxicity of NO is linked to its ability to combine with superoxide anions to form peroxynitrite, an oxidising free radical that can cause deoxyribonucleic acid (DNA) fragmentation and lipid peroxidation. In the mitochondria, peroxynitrate acts on the respiratory chain complex and manganese superoxide dismutase to generate superoxide anions and hydrogen peroxide respectively (3),(4).

NO is a vasoactive substance which is produced by endothelial cells. NO is a vasodilator and has been believed to be decreased in pre-eclampsia (7).

Recent studies have revealed that NO can also modulate apoptosis or programmed cell death in a variety of cell types, including human inflammatory cells. Apoptosis of inflammatory cells is a highly regulated process whereby cellular death occurs without disruption of the cell membrane and by the subsequent release of pro-inflammatory and histotoxic contents of the dying cell (8). NO can be both pro and anti-apoptotic, depending on local concentration and the specific cell type in question. Current evidence suggests that lower concentrations of NO produced by eNOS and nNOS are cytoprotective, while supraphysiological concentrations produced by the iNOS trigger cell death. This paradox may be explained, at least in part, by the free radical nature of NO and hence, the ease with which it reacts with other radicals, particularly reactive oxygen species (ROS), present in the milieu to form various NO-related species in vivo (4).

Endothelial cell dysfunction can be linked to vascular diseases such as atherosclerosis and hypertension. Endothelial cells produce biologically active molecules such as prostacyclins, NO and endothelins. These molecules are believed to play a major role in the control of vascular diameter and tone. It is now believed that the dysfunction of endothelial cells can contribute to inappropriate vasoconstriction and platelet aggregation, which are early signs of atherosclerosis, hypertension and coronary and cerebral vasospasm or thrombosis (7).

Moncada et al showed that other situations in which high amounts of NO may be synthesized include inflammation, re-endothelialisation and angiogenesis. In these situations, the inducible isoforms of iNOS, the enzyme that catalyzes the formation of NO from the terminal guanidino nitrogen of L-Arginine, are expressed after induction by cytokines or endotoxins. Regarding angiogenesis, a process that is highly relevant to proliferative vitreoretinal disorders, NO has been shown to be a potent inhibitor of the cytokine-induced proliferation of endothelial cells (3).

Various authors suggested that tumour cells utilize certain NO-mediated mechanisms for the promotion of growth, invasion and metastasis and proposed that NO-blocking drugs may be useful in treating certain human cancers. There is also evidence that tumour-derived NO promotes tumour angiogenesis as well as the invasiveness of certain tumours in animals, including humans (9).

NOS Expression in Tumours
The first report of NOS expression in human tumour cell lines belongs to Radomski et al (1991), who studied human colorectal adenocarcinoma cell lines from a primary tumour (SW-480) and a lymph node metastasis (SW-620) derived from the same patient. Both cell lines were shown to express constitutively, a calcium-independent NOS activity. The constitutive expression of calcium dependent NOS has also been reported in the cervical epithelial cell line, ME-180 (10).

Fujimoto et al detected the increased expression of iNOS in 74% and 96% of malignant mesotheliomas and metastatic pleural adenocarcinomas, respectively and the expression of iNOS was found to be more in epithelial and mixed mesotheliomas as compared to the sarcomatoid subtype. They also observed that eNOS was found in 89% of the mesotheliomas and there was prominent iNOS and nNOS expression in metaplasia-dysplasia-lesions. So, they postulated that there was a divergent role of NOS in carcinogenesis and the destruction of the alveolar epithelium in the emphysematous lung. It was also observed by them, in samples obtained from patients of lung cancer, that iNOS was detected in 40% cases, while 89% and 81% cases were positive for eNOS and nNOS, respectively. It was also observed that increased levels of eNOS was seen more often in adenocarcinomas than in squamous cells carcinomas and raised levels of iNOS was seen more often in grade I-II tumours than in grade III tumors (11).

Pan JW et al estimated the eNOS and VEGF levels in blood samples from 37 patients of primary astrocytomas and four patients of astrocytic hyperplasia. They suggested that eNOS and VEGF may have a cooperative effect in tumour angiogenesis and may play an important role in the pathogenesis of primary astrocytoma (12).

Zhan et al conducted a study in 26 patients of choledochal cyst to assess the relationship between the expression of iNOS and the p53 gene, as well as the pathogenesis of choledochal cysts. Hyperplasia of the mucosa of the cysts and the amylase level in the bile were also investigated by them. It was observed by them that patients with a high level of amylase in the bile had higher expression of iNOS than those with a low level of amylase and a higher expression of iNOS was related to hyperplasia and carcinogenesis of the mucosa of choledochal cysts (13).

Jaiswal et al observed that there was increased expression of iNOS in gastrointestinal malignancies and NO contributed to carcinogenesis in gastrointestinal tissues by causing DNA lesions, thus inhibiting DNA repair enzymes such as human 8-oxodeoxyguanosine DNA glycosylase1, blocking apoptosis via nitrosylation of caspase and functioning as an angiogenesis factor (14).

Vaninetti et al studied patterns of p53 mutations and the expression of iNOS in oesophageal adenocarcinomas. They noticed a progressive increase in the iNOS messenger ribonucleic acid (mRNA) expression in tissues (63%) in oesophageal adenocarcinoma (15).

Begnami et al compared the expressions of apoptosis related proteins and NOS between Epstein Barr virus (EBV) positive and EBV negative gastric carcinoma. They observed raised expressions of NOS-1 and NOS-3 in EBV associated gastric carcinoma and postulated that EBV positive gastric carcinoma showed a high expression of cNOS that could influence tumour progression and aggressiveness (16).

Gunel et al, in their study, measured serum interleukin-18 (IL-18) and nitrate and the nitrite levels in 56 patients with non-metastatic breast cancer and 14 control subjects. They observed that serum IL-18 and nitrate and nitrite levels were significantly higher in patients with breast cancer when compared to the control subjects. They demonstrated that increased NO activity positively correlated with oestrogen receptor (ER) expression in breast carcinoma. It was postulated by them that serum IL-18 and NO activity can serve as a prognostic predictor in patients with breast cancer (17).

MacLeod et al found that the rate of breast tumour growth and metastasis was significantly reduced when a dietary component of protein (arginine that is needed for the synthesis of NO) was removed from the diet of mice (18).

Marcelo et al, in their study, analysed the expression of iNOS in 15 untreated patients with acute myeloid leukaemia (AML) and in 7 normal controls. By using flow cytometry and immunocytochemistry, they demonstrated that patients with AML had a high expression of iNOS when compared to controls (19).

Zhao et al investigated the expression of the different isoforms of NOSs in B cell-Chronic lymphocytic leukemia (B-CLL) to delineate a possible role for NO in the control of the apoptosis of the tumoral cells. They observed that all B-CLL cells expressed iNOS mRNA, whereas eNOS mRNA was undetectable. It was also found by them that the NO released, exerted an anti-apoptotic effect on B-CLL cells (20).

NO as an Inhibitor of Tumour Growth
In human tumours, the role of NO has not been established. NO produces multiple effects that can influence the outcome of tumour growth and metastasis. This molecule regulates vasodilatation and platelet aggregation (21),(22),(23) which affect tumour cell arrest in capillaries24. NO is also a major cytotoxic mediator which is secreted by activated macrophages25 and endothelial cells24. It is shown to be responsible for the destruction of tumour cells passing through capillary beds. The production of endogenous NO is associated with the apoptosis of tumorigenic cells (26),(27). Cytotoxicity as a result of a substantial NO-formation is established to initiate apoptosis which is characterized by the upregulation of the tumour suppressor p53, changes in the expression of pro- and anti-apoptotic Bcl-2 family members, cytochrome c relocation, activation of caspases, chromatin condensation and DNK fragmentation (28). Taken together, these results suggest the possibility that the production of endogenous NO may be detrimental to tumour cell survival and the production of metastasis (27). Numerous in vivo and in vitro studies support this hypothesis (26),(29),(30). An inverse correlation has been found between the production of endogenous NO and the ability of circulating K-1735 tumour cells to survive and produce metastases (30). The data demonstrates that the introduction of an enzymatically active iNOS gene into highly metastatic murine melanoma K-1735 C4 cells (which express low levels of iNOS) induces apoptosis, suppresses growth and abrogates metastasis (29). Some other reports have also suggested that the expression of iNOS can influence tumour growth and metastasis by regulating vasodilatation and platelet aggregation (21),(31), inhibiting angiogenesis (32) and inducing programmed cell death (28),(33).

NO as a Promotor of Tumour Growth
While NO had been shown to have anti-tumour properties (34), Jenkins et al (35) first reported the surprising finding that human carcinoma cells transfected with a murine iNOS cDNA cassette (DLD-1 cells generating 20 pmol min-1 mg-1 NOS activity) showed increased tumour growth, rather than decreased growth. By using a nude mouse/xanograft model, it was shown that the growth of these NO-generating tumours was accompanied by increased neovascularization. These results were supported by Ambs et al, who used recombinant iNOS expressing Calu-6 and HT-29 human carcinoma cell lines containing mutant p53 (36) to look at tumour growth. The authors demonstrated that an NO-mediated up-regulation of VEGF corresponded with increased vascularisation in the xenograft tumours. Therefore, it is possible that NO generated by NOS (located either within the tumour or in the surrounding stroma) may promote new blood vessel formation by up-regulating VEGF. This neovasculaturization not only enhances the ability of the tumour to grow, but also increases its invasiveness and metastatic ability.

The role of NO in tumorigenesis is multifactorial. NO could participate
in the complicated process of carcinogenesis by mediating DNA damage in the early phases of tumorigenesis and support tumour progression through the induction of angiogenesis and the suppression of the immune response (9). It has been demonstrated that oxygen radicals and nitrogen oxide derivatives such as peroxynitrite and nitrogen dioxide can effectively damage DNA despite the presence of multiple antioxidant defense and repair systems. Such damage is thought to make a significant contribution to the age-related development of cancer (37). It is also proposed that increased NO production may select mutant p53 cells and contribute to human carcinogenesis and tumour progression (38). Furthermore, bradykinin is known to activate an eNOS. Because bradykinin is generated effectivelly in tumours, the bradykinin-NO interplay may become an important issue in tumour growth (37). The invasion-stimulating effects of NO are also due to the upregulation of matrix metalloproteases and the down regulation of their natural inhibitors. Recent reports implicate NOS involvement in the degradation of articular cartilage and show that NO activates metalloproteinase enzymes in chondrocytes and cartilage tissue from human, bovine and rabbit sources. The subsequent loss of integrity of the extracellular matrix and the basement membranes would promote angiogenesis, invasion and the metastatic process (38),(40).

Possible Mechanisms for the Dual Effect of NO on Tumour
It is proposed that low concentrations of NO can be pro-angiogenic and pro-tumour growth inducers, whereas higher NO concentrations can have the opposite effects (41). The effect of NO production in tumour biology may change during tumour progression (38). This hypothesis is supported by data investigating the role of NO in cancer metastasis. After in vitro incubation with cytokines or lipopolysaccharide (LPS), non-metastatic cells exhibited a high level of inducible NOS activity and NO production, whereas metastatic cells did not (42). Cancer growth can be stimulated as well as inhibited by the immune system. The intratumoural macrophageal arginine metabolism is one molecular explanation for the dual ability of the immune system to inhibit or stimulate tumour growth. It has been suggested that arginine metabolism in the tumour bed, yielding citrulline and NO, favours tumour rejection, whereas the production of ornithine and urea could promote tumour growth (43).

Role of NO in Cancer Treatment
Several studies have demonstarted that NO releasing agents can kill tumour cells and as a consequence, there have been attempts to deliver NO to cells. While NO-releasing drugs are under developement, an attractive alternative mechanism for delivery would be to transfer NOS- encoding cDNA sequences into cancer cells for gene therapy purposes (44). Several studies have shown that this approach may work. For example, by using a mouse model, it was demonstarted that the transfection of K-1735 melanoma cells with an iNOS cDNA expression cassette suppressed tumourogenicity and abrogated metastasis (45). Transfection of human renal carcinoma cells with a retroviral iNOS cassette showed similar results (46). A problem with current approaches however, is that the constitutive expression of NOS can quickly result in the death of the transfectant, thus shortening the time in which NO can be generated and potentially limiting the utility of the approach. NOS transfectants often have to be cultured under conditions that reduce toxicity (for example, in the presence of a NOS inhibitor) and transfection attempts may result in cells that are capable of relatively low levels of NO-generation (36). As discussed above, this may result in concentrations of NO that promote tumour growth rather than cell killing. Another significant point is that NOS enzyme activity requires a panel of substrates and co-factors for full activity and these may be missing from the target cell type. For example, the synthesis of the important co-factor, tetrahydrobiopterin (BH4), requires transcriptional regulation of the rate- limiting enzyme GTP cyclohydrolase,which may not be induced in all target cells (47).

Tumour cytokine therapy using Interleulin- 2 (IL-2), IL-1β, or cytokine-inducing agents such as flavone acetic acid (FAA) or analogues, has been shown to induce NOS inman. Several of these studies associate increased NO production with the toxic effects of cytokine therapy, such as circulatory changes and hypotension. But there are studies indicating that patients with the highest plasma nitrate levels show the highest response to the therapy (39), (48). It has also been proposed that selected NO blocking drugs may be useful in the treatment of certain human cancers – either as single agents or as a part of combined therapies. In accordance with that, the treatment of tumour-bearing mice with NO-blocking agents reduce the growth and vascularity of primary tumours and their spontaneous metastases (9). The NO-inhibitory ϖ3 polyunsaturated fatty acids are known to reduce the risk of colon cancer in both man and rat (49). Arginine analogues block the promotional phase of the neoplastic transformation of mouse fibroblasts. On the other hand, they could potentiate the pulmonary metastasis of Lewis lung carcinoma and B16 melanoma cells (50).

Radiotherapy and NO
One of the major factors that limits the effectiveness of radiation therapy is the presence of radioresistant hypoxic tumour cell populations. Over the past 50 years, there has been a concerted effort to identify the agents which are effective hypoxic cell radiosensitizers. To date, there have been few substances which are able to effectively overcome the hypoxic effect. However, several papers have reported that NO can radiosensitize hypoxic cells extensively. Howard-Flanders first showed in 1957 that NO radiosensitized hypoxic bacteria (51). Nearly four decades later, it was shown that NO and NO donor compounds effectively radiosensitize hypoxic mammalian cells too, with a substance enhancement ratio (SER) of 2.4 (52). These findings demonstrate that NO is equally as effective as oxygen at enhancing the sensitivity of hypoxic cells to radiation.
NO-mediated radiosensitization of hypoxic cells is proposed to occur via a mechanism which is similar to that of oxygen molecules (O2) (51),(52). Carbon-centered radicals are initially generated by ionizing radiation on DNA. In the absence of NO or O2, these reactive radicals scavenge the nearby protein hydrogen atoms, thus facilitating DNA repair. This process limits the number of DNA lesions per photon. However, it has been postulated that NO reacts with these high energy carbon-centered radicals to form complexes which are not capable of abstracting protein hydrogen atoms. The fixing of the radiation induced damage increases the number of lesions per photon, thus increasing radiation-mediated cell death. An advantage of using NO as a hypoxic cell radiosensitizer is that it penetrates into the tissue farther than oxygen due to its higher diffusion coefficient (53),(54). The lower concentrations of NO and the higher diffusion rates suggest that NO may be an ideal candidate for new strategies in radiotherapy.


Thus, NO can be considered to be a ‘double edged sword' in cancer. High concentrations may mediate cancer call apoptosis and the supression of cancer growth, while low concentrations may promote tumour growth and proliferation. It is also important in understanding the treatment protocol and the various modalities being used in the treatment of various cancers. Thus, NO performs a multifactorial role and appears to be a promising molecule for further research in the diagnosis, management and monitoring of cancer patients.


Jayanta De, Maity CR (2003). Nitric oxide: A magic molecule. Indian J Med Biochem 7: 53-67.
Furchgott RF, Khan MT, Jothianandam KM (1987). Similarities of behaviour of metric relaxing factor in a perfusion cascade bioassay system. Fed Proc 46: 385-91.
Moncada S, Palmer RMJ, Higgs EA (1991). Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43: 109-42.
Beevi SSS, Rasheed AMH, Geetha A (2004). Evaluation of oxidative stress and nitric oxide levels in patients with oral cavity cancer. Jpn J Clin Oncol 34 (7): 379-85.
Wang Y (1995). Nitric oxide synthases: gene structure and regulation. Adv Pharmacol 34: 71-90.
Naush LW, Ledoux J, Bones AD, Nelson MT, Dostman WR (2008). Differential patterning of cGMP in vascular smooth muscles revealed by single GFP- linked biosensors. Proc Natl Acad Sci USA 105: 365-80.
Vallance P, Leone A, Calver A (1992). Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 20: 60-2.
Tylor EL, Megson I (2003). Nitric oxide: a key regulator of myeloid inflammatory cell apoptosis. Cell Death Differ 10; 418-30.
Lala PK, Orucevic A (1998). Role of nitric oxide in tumour progression: lessons from human tumours. Cancer and Metastasis Review 17: 91-106.
Radomski M W, Jenkins DC, Holms L, Moncada C (1991). Human colorectal adenocarcinoma cells: Differential nitric oxide synthesis determines their ability to aggregate platelets.Cancer Res 51: 6073-8.
Fujimoto (1997). Nitric oxide synthases and reactive oxygen species damage in pleural and lung tissues and neoplasia. Jpn J Cancer Res 88:1190-8.
Pan JW, Zhan R, Tong Y, Zhou Y, Zhang M (2005). Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytomas. J Zhejiang Univ Sci B 6:693-8.
Zhan JH, Hu XL, Dai CJ, Niu J, Gu JQ (2001). Expressions of p53 and inducible nitric oxide synthase in congenital choledochal cysts and factors of biliary carcinogenesis in choledochal cysts. Eur J Pediatr Surg 11:24-7.
Meeta J, Nicholas F, LaRusso, Gregory JG (2001). Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 281:626-34.
Vaninetti NM, Geldenhuys L, Porter GA, Risch H, Hainaut P, Guernsey DL,et al (2008). Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinomas. Mol Carcinog 47: 275-85.
Maria DB (2006). Differential expression of apoptosis related proteins and nitric oxide synthases in Epstein Barr associated gastric carcinomas. World J Gastroenterol 12: 4952-6.
Gunel R, Nazan D, Coskun H, Ugur K, Sancak R, Banu L, et al (2003). Prognostic Value of Serum IL-18 and Nitric Oxide Activity in Breast Cancer Patients at Operable Stage. Am J Clin Oncol 26: 416-21.
MacLeod CL (2001). Nitric Oxide and Arginine in Normal and Tumorous Breast. J Biol Chem 276: 881-5.
Brandao MM, Soares E, Salles TS, Saad ST (2001). Expression of inducible nitric oxide synthase is increased in acute myeloid leukemia. Acta Haematol 106: 95-9.
Zhao H, Dugas N, Mathiot C, Delmer A, Dugas B, Sigaux F, et al (1998). B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 92:1031-43.
Radomski MW, Palmer RMJ, Moncada S (1990). An L-arginine/nityric oxide pathway, present in human plateletes aggregation. Proc Natl Acad Sci USA 87:5193-7.
Dawson TM, Dawson VL (1995). Nitric oxide: Actions and pathological roles. Neuroscientist 1: 1-19.
Gross SS, Volin MS (1995). Nitric oxide: Pathological mechanisms. Ann Rev Physiol 57: 737-69.
Li L, Kilborn RG, Adams J, Fidler IJ (1991). Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Res 51: 2531-5.
Nathan C, Xie QW (1994). Nitric oxide synthetases: roles, toles and controls. Cell 78: 815-919.
Cui S, Reichner JS, Mateo RB, Albina JE (1994). Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or-independent mechanisms. Cancer Res 54: 2462-7.
Weigert A, Brune B (2008). Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric oxide and Cancer: Clinical and Therapeutic Implications 2 (19): 95-102.
Brune B, Knethen A, Sandau KB (1999). Nitric oxide (NO): an effector of apoptosis. Cell Death Differentiation 6: 969-75.
Xie K, Huang S, Dong Z, Gutman M, Fidler IJ (1995). Direct correlation between expression of endogenous inducible nitric oxide synthetase and regression of M5076 hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Cancer Res 55: 3123-31.
Dong Z, Staroselsky AH, Qi X, Xie K, Fidler IJ (1994). Inverse correlation between expression of inducible nitric oxide synthetase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res 54: 789-93.
Palmer PMJ, Rees DS, Ashton DS, Moncada C (1988). Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (Lond) 333: 664-6.
Sakkoula E, Haralabopoulos G, Andriopolou P, Peristeris P, Maragoudakis ME (1994). Evidence that nitric oxide is an endogenous antiangiogenic mediator.Br J Pharmacol 111: 894-902.
Albina JE, Cui S, Mateo RB, Reichner JS. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol 150: 5080-5.
Hibbs JB Jr, Taintor RR, Vavrin Z (1987). Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 235:473-6.
Jenkins DC, Charles IG, Thomsen LL, et al (1995). Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92:4392-6.
Ambs S, Merriam WG, Ogunfusika MO, et al (1998). p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 4:1371-6.
Maeda H, Akaide T (1998). Nitric oxide and oxygen radicals in infection, inflammation and cancer. Biochemistry (Moscow) 7: 1007-19.
Ambs S, Hussain SP, Harris CC (1997). Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J 11: 443-8.
Thomsen LL, Miles D (1998). Role of nitric oxide in human progression: lessons from human tumours. Cancer Met Rev 17: 107-18.
Hassan MS, Mileva M, Dweck H, Rosenfeld L (1998). Nitric oxide products degrade chondroitin sulfates. Nitric oxide: Biology and chemistry, 215, 1998, 360-365.
Chinje EC, Stratford IJ (1997). Role of nitric oxide in growth of solid tumors: a balancing act. Essays Biochem 32: 61-72.
Xie K, Dong Z, Fidler IJ (1996). Activation of nitric oxide synthetase gene for inhibition of cancer metastasis. J Leuk Biol 59: 797-803.
Murta BMT, Machado JS, Zaparoli M, Lara VC, Murta EFC (1999).The relationship of host immune cells, cytokines and nitric oxide production to tumor cells in ovarian carcinoma. – Sao Paulo Med J 2: 87-92.
Xu W, liu LZ, loizidou M, Ahmed M, charles IG (2002). The role of nitric oxide in cancer. Cell Research 12: 311-20.
Xie K, Huang S, Dong Z. et al (1995). Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 181:1333-43.
Juang SH, Xie K, Xu L, et al (1998). Suppression of tumorigenicity and metastasis of human renal carcinoma cells by infection with retroviral vectors harboring the murine inducible nitric oxide synthase gene. Hum Gene Ther 9:845-85.
Tzeng E, Yoneyama T, Hatakeyama K, Shears LL, 2nd & Billiar TR (1996). Vascular inducible nitric oxide synthase gene therapy: requirement for guanosine triphosphate cyclohydrolase I. Surgery 120:315-21.
Miles DW, Thomsen LL, Balkwill, Thavasu P, Moncada S (1994). Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin-2. Eur J Clin Invest 24: 287-90.
Alexandrova R, Mileva M, Zvetkova E. Nitric oxide and Cancer (Minireview) (2001). Exp Path Parasitol 4/7: 13-8.
Zidek Z, Masek K (1998). Erratic behavior of nitric oxide within the immune system: illustrative review of conflicting data and their immunopharmacological aspects. Int J Immunopharmacol 20: 319-43.
Howard-Flanders P (1957). Effect of nitric oxide on the radiosensitivity of bacteria. Nature 180: 1191-2.
Mitchell J B, Wink DA, DeGraff W, Gamson J, Keefer LK, Krishna MC (1993). Activation of inducible nitric oxide synthase results in nitric oxide mediated radiosensitization of hypoxic EMT-6 tumor cells. Cancer Res 53: 5845-8.
Christos H (2003). Nitric oxide: A new concept in radiopharmacology. Journal of BUON 8: 209-16.
Wink D A, Vodovotz Y, Cook J A, Krishna M C, Kim S, Coffin D, DeGraff W, Deluca A M, Liebmann J, Mitchell J B (1998). The role of nitric oxide chemistry in cancer treatment. Biochemistry 63(7): 802-9.

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)